미국의 희귀의약품 시장 규모는 2025-2032년의 예측 기간 중 10.25%의 CAGR로 확대하며, 2024년 903억 9,000만 달러에서 2032년에는 1,973억 1,000만 달러로 성장할 것으로 예측됩니다. 미국의 희귀질환 치료제 시장은 희귀질환 유병률 증가와 진단 강화로 인해 강력한 성장세를 보이고 있습니다. 시장 독점권 및 세액 공제 등의 정부 혜택은 의약품의 기술 혁신을 촉진하고 있습니다. 또한 암 분야는 여전히 가장 큰 시장이며, 희귀암 치료에 대한 관심이 높아지면서 시장 확대가 가속화되고 있습니다.
2024년 9월 11일, 희귀질환 치료제 개발에 전념하는 세포 대사 및 PK 활성화 분야의 선두주자인 Agios Pharmaceuticals, Inc.(AG-946)이 미국 식품의약국(FDA)으로부터 희귀의약품으로 지정되었다고 발표했습니다.
미국의 희귀의약품 시장에 대해 조사했으며, 시장의 개요와 치료 분야별, 약제 유형별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
United States orphan drugs market is projected to witness a CAGR of 10.25% during the forecast period 2025-2032, growing from USD 90.39 billion in 2024 to USD 197.31 billion in 2032. The U.S. orphan drugs market is witnessing strong growth due to rising rare disease prevalence and enhanced diagnostics. Government incentives like market exclusivity and tax credits are encouraging pharmaceutical innovation. Additionally, oncology remains the largest segment, with increasing focus on rare cancer therapies accelerating market expansion.
For instance, on September 11, 2024, Agios Pharmaceuticals, Inc., a frontrunner in cellular metabolism and PK activation dedicated to developing therapies for rare diseases, announced that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to its innovative pyruvate kinase (PK) activator, tebapivat (AG-946), intended for the treatment of myelodysplastic syndromes (MDS).
Rising Prevalence of Rare Diseases Fueling Demand for Orphan Drugs
The rising incidence of rare diseases in the United States has markedly increased the demand for orphan drugs. The National Institutes of Health (NIH) reports that around 7,000 rare diseases impact more than 30 million Americans. Many of these conditions lack adequate treatment options, leading to a significant unmet need for specialized therapeutics. Orphan drugs are designed specifically for these diseases, and their market has expanded due to heightened awareness, earlier diagnoses, and advancements in genetic testing. Additionally, the U.S. Food and Drug Administration (FDA) has introduced various incentives, including tax credits, market exclusivity, and accelerated approval processes, to promote the development of orphan drugs. These measures have led to a rise in research and development investments from pharmaceutical companies. For instance, in February 2024, Amgen received FDA approval for BLINCYTO (blinatumomab), an orphan drug for the treatment of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients. This approval not only adds to Amgen's oncology pipeline but also highlights the industry's growing commitment to addressing rare disease burdens.
Government Incentives and Regulatory Support Accelerate Orphan Drug Approvals
The proactive regulatory framework established by the U.S. government significantly drives the orphan drug market. The Orphan Drug Act of 1983 provided essential regulatory and financial incentives, including seven years of market exclusivity, research grants, and tax credits for clinical trials. These advantages motivate biotech and pharmaceutical companies to pursue the development of treatments for rare diseases, even with limited patient populations. The FDA's Office of Orphan Products Development (OOPD) is instrumental in accelerating these therapies' review and approval processes through initiatives such as Fast Track, Breakthrough Therapy, and Priority Review designations. In recent years, this supportive environment has resulted in a notable increase in orphan drug designations and approvals. A notable example is when Acadia Pharmaceuticals Inc. had declared in the U.S. in March 2023, that the U.S. Food and Drug Administration (FDA) had approved DAYBU (trofinetide) to treat Rett syndrome in both adult and pediatric patients aged two years and older. DAYBUE is the sole medication authorized to treat Rett syndrome. The approval underlines how streamlined pathways and strong regulatory backing are helping more orphan drugs reach patients faster, boosting innovation and accessibility in the U.S. market.
Oncology Segment Dominates with Increasing Development of Rare Cancer Therapies
Oncology represents the largest U.S. orphan drugs market segment among various therapeutic areas. The increasing prevalence of rare cancers, including soft tissue sarcomas, gliomas, and specific blood malignancies, has notably heightened the demand for specialized treatment options. Pharmaceutical firms are sharpening their focus on developing targeted therapies and immuno-oncology medications that provide enhanced effectiveness and reduced side effects compared to traditional treatments. The robust presence of biotechnology companies, investments in precision medicine, and a growing pipeline of clinical trials in the U.S. further bolstered this sector's growth. Additionally, the orphan drug designation for oncology products frequently results in expedited regulatory approvals, lower development expenses, and prolonged market exclusivity, rendering it a highly profitable domain. For instance, in August 2023, Bristol Myers Squibb received FDA approval for REBLOZYL (luspatercept-aamt) as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes, which includes certain rare cancers. This approval under the Orphan Drug Act highlights the market's strong momentum in rare oncology therapeutics.
Future Market Scenario (2025-2032F)
The orphan drugs market in the United States is set for significant expansion, driven by a growing awareness of rare diseases, favorable regulatory frameworks, and vigorous research and development efforts by pharmaceutical firms. Innovations in genomics and personalized medicine facilitate the discovery of new therapeutic targets, while expedited FDA approval processes are shortening the time required for orphan-designated drugs to reach the market. Additionally, the increasing presence of patient advocacy organizations and advancements in diagnostics are enhancing access to therapies for rare diseases. The prevalence of biologics and heightened investments in gene and cell therapies will likely transform the treatment landscape. With major industry players actively working on innovative pipeline projects, the market is expected to maintain its momentum, providing renewed hope for underrepresented patient populations across diverse therapeutic fields.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of orphan drugs and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, Rapid Commercialization Partners (RCP) has joined forces with Orphan Now to assist companies in accelerating the development of orphan drugs. This collaboration seeks to facilitate market entry, thereby providing quicker access to essential treatments for patients globally. The initiative improves the efficiency of commercialization, offering advantages to developers of drugs for rare diseases.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.